创建

登录 ReadmeX

或

了解我们如何处理你的信息: 隐私政策

ReadmeX

陪你读懂 AI 动态

今天,想先了解什么?

选一份动态总结,或直接聊聊你的问题。

社区和关注动态总结只属于你自己。

资讯

Boltz获1.1亿美元A轮融资

AI 总结

总部位于伦敦的Boltz完成由Bessemer Venture Partners领投的1.1亿美元A轮融资,此前公司于2025年获得2800万美元种子轮融资。Boltz通过Boltz Lab和API提供BoltzMol-1、BoltzProt-1,服务分子筛选和蛋白质设计,但不运营自有药物研发管线。公司称自6月以来客户Token使用量增长50倍,且全球前20大制药公司中有6家为其客户,但现有报道未独立核实这些使用与客户数据。

深度见解

这笔融资将帮助Boltz扩充算力、团队和模型研发,进一步探索按使用量销售分子设计AI的商业模式。

Boltz PBC, a startup that develops artificial intelligence models for pharmaceutical researchers, has raised $110 million in funding.

Bessemer led the Series A investment. Boltz stated on Wednesday that the fund was joined by a large group of new and returning backers. The consortium included Greycroft, Andreessen Horowitz, Amplify Partners, F-Prime Capital, Hummingbird and others.

Small molecules, the building blocks of many drugs, can only neutralize a pathogen after binding to it. As a result, researchers start drug discovery projects by looking for molecules that have a high binding affinity with pathogens. They often review hundreds of thousands of candidate molecules per project. The process can take months and often costs millions of dollars.

Boltz offers an AI model called BoltzMol-1 that speeds up the workflow. It generates binding affinity data by reviewing only a few dozen, particularly promising molecules instead of the hundreds of thousands usually needed. The fewer molecules need to be studied, the less time the analysis takes.

Binding affinity evaluations don’t yield drug discoveries right away. Instead, they produce data points called small molecule hits. Those are essentially faint clues that help researchers pinpoint the area where they should focus their efforts.

#Boltz#Bessemer Venture Partners#Andreessen Horowitz#BoltzMol-1#BoltzProt-1#Boltz Lab#Boltz API

原文约 3 分钟读完阅读原文
群聊

还没有评论,来说说你的看法。